IFNB1 and familial pancreatic carcinoma: Since gemcitabine is much better tolerated with less toxicity compared to the newer chemotherapeutic agents, especially in the elderly pancreatic cancer patients, we aimed to evaluate whether the anti-tumor effect of gemcitabine could be enhanced by IFN-β and to demonstrate the mechanism of action.